



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Arti-Cell Forte Suspension for Injection for Horses Vm 04491/5062

• 25 October 2022	To update information on the manufacturing process of the active substance.
• 12 October 2022	Minor changes to an approved change management protocol of the active substance that does not change the strategy defined in the protocol.
• 31 August 2022	Update to product labelling for a name change of a manufacturer responsible for batch release.
• 12 April 2022	Change to an approved stability protocol.
• 24 November 2021	Change in the name of a manufacturer used in the manufacture of the active substance. Change in the name of a manufacturer of the finished product, also responsible for batch release.
• 24 November 2021	Introduction of a new pharmacovigilance system.
• 07 July 2021	Change of MAH, from Global Stem cell Technology NV, Noorwegenstraat 4, 9940 Evergem, Belgium to Boehringer Ingelheim Vetmedica GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany.
• 04 June 2021	Extension of a storage period of the active substance. Change to an approved stability protocol.